OverviewSuggest Edit

KemPharm is a biopharmaceutical company focused on the discovery and development of new, safer therapies in the areas of pain, ADHD, and other CNS diseases. Its primary efforts include the development of safer, abuse resistant opioid pain relievers. KemPharm’s drug discovery and development platform is based on its proprietary Ligand Activated Therapy (LAT) approach. The Company uses its patent-applied technology to improve existing drugs and shorten the development timeline while still maintaining a strong intellectual property position within each therapeutic area.
TypePublic
Founded2006
HQKissimmee, FL, US
Websitekempharm.com

Latest Updates

Employees (est.) (Dec 2018)33(+4%)
Revenue (FY, 2020)$13.3 M(+4%)
Share Price (Apr 2021)$10.4(+6%)
Cybersecurity ratingAMore

Key People/Management at KemPharm

Travis C. Mickle

Travis C. Mickle

President, Chief Executive Officer and Chairman of the Board, Co-Founder
Christal M.M. Mickle

Christal M.M. Mickle

Vice President, Operations and Product Development; Co-Founder
Richard W. Pascoe

Richard W. Pascoe

Lead Independent Director and Chair, Audit Committee
Sven Guenther

Sven Guenther

Executive Vice President, Research and Development
Andrew Barrett

Andrew Barrett

Vice President, Scientific Affairs
Rene A. Braeckman

Rene A. Braeckman

Vice President, Clinical Development
Show more

KemPharm Office Locations

KemPharm has offices in Kissimmee, Blacksburg and Coralville
Kissimmee, FL, US (HQ)
1180 Celebration Blvd #103
Blacksburg, VA, US
2200 Kraft Dr SW STE 2425
Coralville, IA, US
2656 Crosspark Rd #100
Coralville, IA, US
BioVentures Center, 2500 Crosspark Rd e126
Show all (4)

KemPharm Financials and Metrics

KemPharm Revenue

KemPharm's revenue was reported to be $13.29 m in FY, 2020
USD

Revenue (FY, 2020)

13.3m

Net income (FY, 2020)

(12.8m)

EBIT (FY, 2020)

(5.6m)

Market capitalization (7-Apr-2021)

294.5m

Closing stock price (7-Apr-2021)

10.4

Cash (31-Dec-2020)

4.2m

EV

359.1m
KemPharm's current market capitalization is $294.5 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

12.8m13.3m

Cost of goods sold

10.0m

Gross profit

2.8m

Gross profit Margin, %

22%
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

11.5m2.1m6.9m1.9m

Cost of goods sold

1.0m

Gross profit

10.5m

Gross profit Margin, %

91%
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

32.3m16.8m10.9m18.4m3.2m4.2m

Accounts Receivable

2.0m140.0k1.7m2.4m

Prepaid Expenses

1.7m2.1m1.6m1.5m

Inventories

2.8m489.0k
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

10.3m64.2m59.0m77.3m27.5m20.8m12.9m12.4m7.8m8.8m16.5m1.8m13.4m7.3m6.5m2.4m6.4m5.3m

Accounts Receivable

2.5m1.5m1.6m2.3m2.1m2.2m

Prepaid Expenses

53.0k607.0k607.0k386.0k824.0k636.0k795.0k771.0k1.4m1.8m1.6m2.6m1.9m1.3m528.0k890.0k603.0k675.0k

Current Assets

10.3m64.8m59.6m111.4m84.6m65.3m63.0m55.4m50.2m39.1m30.9m16.7m15.3m8.6m8.7m5.5m9.1m8.1m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(54.7m)(16.5m)(43.4m)(56.5m)(24.5m)(12.8m)

Depreciation and Amortization

84.0k175.0k336.0k324.0k304.0k273.0k

Inventories

(1.2m)(15.9m)

Accounts Payable

1.3m1.1m(801.0k)(1.6m)(3.8m)931.0k
USDQ1, 2015

Financial Leverage

-0.3 x
Show all financial metrics

KemPharm Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

KemPharm Online and Social Media Presence

Embed Graph

KemPharm News and Updates

KemPharm to Report Fourth Quarter and Full Year 2020 Financial Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, March 11, 2021, 4:30 p.m. ET

Thinking about buying stock in Humanigen, Marathon Oil, KemPharm, GoHealth, or SRAX Inc?

NEW YORK, March 5, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HGEN, MRO, KMPH, GOCO, and SRAX. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

KemPharm Announces FDA Approval of AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules, for oral use, CII), A New Once-Daily Treatment for ADHD

Conference Call and Live Audio Webcast Scheduled for Tomorrow, Wednesday, March 3, at 8:30 a.m. ET

Thinking about buying stock in Phio Pharmaceuticals, SRAX Inc, KemPharm, Avadel Pharmaceuticals, or Neovasc Inc?

NEW YORK, March 1, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PHIO, SRAX, KMPH, AVDL, and NVCN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

KemPharm Receives FDA Clearance to Initiate KP879 Clinical Program for the Treatment of Stimulant Use Disorder

Financial Restructuring and Nasdaq Re-Listing Process Completed

KemPharm Participating in BIO @ JPM and Fierce JPM Week 2021 Virtual Events During “J.P. Morgan Week 2021”

CELEBRATION, Fla., Jan. 13, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the company is participating in BIO @ JPM and Fierce JPM Week 2021.  Both events are being h…
Show more

KemPharm Blogs

KemPharm Announces Amendment to Licensing Agreement with Gurnet Point Capital Affiliate Following FDA Approval of AZSTARYS™

KemPharm Announces Amendment to Licensing Agreement with Gurnet Point Capital Affiliate Following FDA Approval of AZSTARYS™ Content Import Thu, 04/08/2021 - 16:07 KemPharm Announces Amendment to Licensing Agreement with Gurnet Point Capital Affiliate Following FDA Approval of AZSTARYS™ …

KemPharm Reports Fourth Quarter and Full-Year 2020 Financial Results

Corporate and Regulatory Highlights: AZSTARYS™ NDA approved by the FDA on March 2, 2021 Co-hosted “KP415 Market Opportunity and Commercialization Strategy” Investor Event with Corium, Inc. Received FDA clearance to initiate KP879 clinical program for the treatment of Stimulant Use Disorder

Jonathan Aschoff, Ph.D.

Jonathan Aschoff, Ph.D. william.meady@… Mon, 03/08/2021 - 10:09 Jonathan Aschoff, Ph.D. Roth Capital jaschoff@roth.com

KemPharm to Present at the 33rd Annual Roth Conference

CELEBRATION, Fla. , March 04, 2021 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle , Ph.D., President and CEO of KemPharm, will present at the 33 rd Annual

KemPharm Announces Pricing of $50 Million Public Offering of Common Stock and Warrants and Uplisting to The Nasdaq Capital Market

Common stock will begin trading on The Nasdaq Capital Market under the ticker symbol “KMPH” today, January 8, 2021   Celebration, FL – January 8, 2021 – KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced…

KemPharm Announces 1-for-16 Reverse Stock Split

CELEBRATION, Fla. , Dec. 23, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company's Board of Directors has approved a 1-for-16 reverse stock split of its shares of
Show more

KemPharm Frequently Asked Questions

  • When was KemPharm founded?

    KemPharm was founded in 2006.

  • Who are KemPharm key executives?

    KemPharm's key executives are Travis C. Mickle, Christal M.M. Mickle and Richard W. Pascoe.

  • How many employees does KemPharm have?

    KemPharm has 33 employees.

  • What is KemPharm revenue?

    Latest KemPharm annual revenue is $13.3 m.

  • What is KemPharm revenue per employee?

    Latest KemPharm revenue per employee is $402.7 k.

  • Who are KemPharm competitors?

    Competitors of KemPharm include AKESOgen, Hospira and Biothera.

  • Where is KemPharm headquarters?

    KemPharm headquarters is located at 1180 Celebration Blvd #103, Kissimmee.

  • Where are KemPharm offices?

    KemPharm has offices in Kissimmee, Blacksburg and Coralville.

  • How many offices does KemPharm have?

    KemPharm has 4 offices.